Synergistic Anti-Tumor Effect of Palmitoylcarnitine and Dasatinib in Liver Cancer
Hepatocellular carcinoma (HCC) is the third major cause of cancer-related death worldwide and responds positively to tyrosine kinase inhibitors (TKIs). Dasatinib (Das) is an Src/Abl family kinase and has been successfully utilized in the treatment of various cancers. Cancer cells are known to limit...
Shranjeno v:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2022-11-01
|
| Serija: | Livers |
| Teme: | |
| Online dostop: | https://www.mdpi.com/2673-4389/2/4/26 |
| Oznake: |
Brez oznak, prvi označite!
|